Prostate Cancer

Implant Sciences to Expand Production Workforce By 50%

Published in Cancer Weekly, October 30th, 2001

Implant Sciences Corp. (IMX), which manufactures I-Plant iodine-125 brachytherapy seeds for the treatment of prostate cancer, will increase its workforce by 50% to meet the growing demand for the seeds.

"We have already installed equipment to handle this new business, and management is currently in the process of hiring and training new employees," said Dr. Anthony J. Armini, president and chief executive officer of Implant Sciences Corp. "We expect to increase our production workforce in Wakefield, Massachusetts by approximately 50% during the next several weeks, to meet the growing demand for our I-Plant radioactive prostate seeds."

MED-TEC Inc.,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry